4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Net Margin of 2256.65% for Q1 2026, up 34040050.0% year-over-year from N/an in Q1 2025, and down 9999.37% quarter-over-quarter from 22.8% in Q4 2025.
4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Net Margin for 7 consecutive years, with 2256.65% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 34040050.0% year-over-year to 2256.65%; the TTM figure through Mar 2026 stood at 182.34% (up 76694375.0% YoY), while the FY2025 annual figure was 164.43%, up 43461395.0% from the prior year.
- Net Margin slipped to 2256.65% in Q1 2026 per FDMT's latest filing, from 22.8% in the prior quarter.
- Across five years, Net Margin topped out at 169910.53% in Q4 2023 and bottomed at 4967100.0% in Q4 2024.
- Historically, Net Margin has averaged 464398.39% across 5 years, with a median of 12391.63% in 2023.
- Annual changes were most pronounced in 2024 — Net Margin sank 513701053 bps — and 2025, when it jumped 496712280 bps.
- 4D Molecular Therapeutics' Net Margin stood at 2195.59% in 2022, then surged by 7839 bps to 169910.53% in 2023, then tumbled by 3023 bps to 4967100.0% in 2024, then surged by 100 bps to 22.8% in 2025, then sank by 9999 bps to 2256.65% in 2026.
- Business Quant data shows FDMT's Net Margin at 2256.65% in Q1 2026, 22.8% in Q4 2025, and 63195.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -1,929.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,929.01% |
| Mar 31, 2026 | -2,256.65% |
| Dec 31, 2025 | 22.80% |
| Sep 30, 2025 | -63,195.56% |
| Jun 30, 2025 | -364,386.67% |
| Mar 31, 2025 | -342,657.14% |
| Dec 31, 2024 | -4,967,100.00% |
| Sep 30, 2024 | -1,461,433.33% |
| Jun 30, 2024 | -699,060.00% |
| Mar 31, 2024 | -115,717.86% |
| Dec 31, 2023 | 169,910.53% |
| Sep 30, 2023 | -50.76% |
| Jun 30, 2023 | -12,391.63% |
| Mar 31, 2023 | -9,624.83% |
| Dec 31, 2022 | -2,195.59% |
| Sep 30, 2022 | -5,138.20% |
| Jun 30, 2022 | -17,337.04% |
| Mar 31, 2022 | -2,160.62% |
| Dec 31, 2021 | -27,264.13% |
| Sep 30, 2021 | -1,628.04% |